Autoimmune haemolytic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Autoimmune haemolytic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-tafasitamab-in-adults-with-autoimmune-thrombocytopenia-or-autoimmune-hemolytic-anemia/ Wed, 29 Apr 2026 15:09:04 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-tafasitamab-in-adults-with-autoimmune-thrombocytopenia-or-autoimmune-hemolytic-anemia/ This study aims to evaluate the safety and effectiveness of tafasitamab in adults living with certain rare conditions where the body’s immune system attacks its own blood cells. These conditions include Immune-mediated thrombocytopenia, which is a disorder that leads to a low number of platelets, the cells responsible for blood clotting, and Autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. In these diseases, the body mistakenly identifies its own blood components as harmful substances and begins to attack them.

The treatment being studied is tafasitamab, which is administered through intravenous infusion. This means the medication is delivered directly into a vein over a set period of time. Participants in the study will receive this medication to see how well it helps stabilize blood cell levels and how the body reacts to the drug.

]]> Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia https://clinicaltrials.eu/trial/study-of-rilzabrutinib-tablets-compared-to-placebo-in-adults-with-warm-autoimmune-hemolytic-anemia/ Wed, 29 Apr 2026 15:06:32 +0000 https://clinicaltrials.eu/trial/study-of-rilzabrutinib-tablets-compared-to-placebo-in-adults-with-warm-autoimmune-hemolytic-anemia/ This clinical study focuses on warm autoimmune hemolytic anemia (wAIHA), a condition where the body’s immune system mistakenly destroys its own red blood cells. The study will test a medication called rilzabrutinib, given as film-coated tablets taken by mouth, compared to a placebo. This is a new treatment approach for people whose disease has not responded well to standard treatments or who cannot take conventional medications.

The research aims to determine if rilzabrutinib can help maintain stable blood levels in people with warm autoimmune hemolytic anemia. During the study, participants will receive either rilzabrutinib tablets or placebo tablets. The maximum daily dose of rilzabrutinib will be 800 mg, and the treatment period will last for 224 weeks.

The study will measure several aspects of the treatment’s effects, including changes in hemoglobin levels (a protein in red blood cells that carries oxygen throughout the body), changes in fatigue levels, and how quickly the treatment works. The study will also track how well participants feel, including their ability to breathe comfortably, and monitor any side effects that may occur during treatment.

]]> Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia https://clinicaltrials.eu/trial/study-on-nipocalimab-for-adults-with-warm-autoimmune-hemolytic-anemia/ Wed, 29 Apr 2026 14:57:07 +0000 https://clinicaltrials.eu/trial/study-on-nipocalimab-for-adults-with-warm-autoimmune-hemolytic-anemia/ This clinical trial is focused on studying the effectiveness and safety of a treatment for a condition called warm autoimmune hemolytic anemia (wAIHA). This is a disease where the body’s immune system mistakenly attacks and destroys its own red blood cells, leading to anemia. The treatment being tested is a medication known as nipocalimab, which is a type of protein called a monoclonal antibody. This medication is given as a solution through an infusion into a vein.

The purpose of the study is to evaluate how well nipocalimab works in treating adults with wAIHA. Participants in the study will receive either nipocalimab or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. After this phase, there will be a long-term extension where all participants may receive nipocalimab.

Throughout the study, participants will have regular visits to monitor their health and the effects of the treatment. The study will assess whether the treatment can improve hemoglobin levels, which are important for carrying oxygen in the blood, without the need for additional rescue therapies. The study aims to provide valuable information on the potential benefits of nipocalimab for people living with wAIHA.

]]> Long-Term Safety Study of Riliprubart in Patients with Cold Agglutinin Disease https://clinicaltrials.eu/trial/long-term-safety-study-of-riliprubart-in-patients-with-cold-agglutinin-disease/ Wed, 29 Apr 2026 14:56:47 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-riliprubart-in-patients-with-cold-agglutinin-disease/ This clinical trial is focused on studying a condition known as Cold Agglutinin Disease (CAD), which is a type of autoimmune hemolytic anemia. In this condition, the body’s immune system mistakenly attacks and destroys its own red blood cells, leading to anemia. The study is investigating a treatment called riliprubart, also known by its code name SAR445088. This treatment is administered as a solution for injection or infusion.

The purpose of the study is to assess the long-term safety and tolerability of riliprubart in individuals with CAD. Participants in the study may have been previously treated with riliprubart or may be receiving it for the first time. The study will involve multiple doses of the medication, and participants will be monitored over an extended period to observe any side effects or changes in their condition.

Throughout the study, researchers will keep track of any new health issues that arise in participants, known as treatment-emergent adverse events. They will also measure changes in various blood components, such as bilirubin and hemoglobin levels, to understand how the treatment affects the body. The study aims to provide valuable information on the long-term use of riliprubart for managing Cold Agglutinin Disease.

]]> Study on the Effects and Safety of Rilzabrutinib for Adults with Warm Autoimmune Hemolytic Anemia https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-rilzabrutinib-for-adults-with-warm-autoimmune-hemolytic-anemia/ Wed, 29 Apr 2026 14:56:43 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-rilzabrutinib-for-adults-with-warm-autoimmune-hemolytic-anemia/ This clinical trial is focused on studying the effects of a medication called Rilzabrutinib in patients with a condition known as warm autoimmune hemolytic anemia (wAIHA). This condition occurs when the body’s immune system mistakenly attacks and destroys its own red blood cells, leading to anemia. The medication being tested, Rilzabrutinib, is taken in the form of a tablet and is designed to help manage this condition by potentially reducing the immune system’s attack on red blood cells.

The purpose of the study is to evaluate how effective and safe Rilzabrutinib is for patients with wAIHA. The study is divided into two parts. In the first part, participants will receive the medication to see how well it works in improving their condition. If the medication shows positive results, participants may continue to the second part, which looks at the long-term effects of the treatment. Throughout the study, participants will be monitored to assess their response to the medication and any side effects they may experience.

Participants in the study will take the medication orally, and their progress will be closely observed by healthcare professionals. The study aims to provide valuable information on the potential benefits of Rilzabrutinib for individuals with wAIHA, contributing to the understanding and management of this condition. The trial will also gather data on the safety of the medication, ensuring that any risks are identified and managed appropriately.

]]> Study on the Effectiveness of Apixaban and Enoxaparin Sodium in Preventing Blood Clots in Patients with Autoimmune Hemolytic Anemia https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-apixaban-and-enoxaparin-sodium-in-preventing-blood-clots-in-patients-with-autoimmune-hemolytic-anemia/ Wed, 29 Apr 2026 14:27:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-apixaban-and-enoxaparin-sodium-in-preventing-blood-clots-in-patients-with-autoimmune-hemolytic-anemia/ This clinical trial is focused on studying the effectiveness of a treatment for patients with Autoimmune Hemolytic Anemia (AIHA), a condition where the immune system mistakenly attacks and destroys red blood cells. The study aims to prevent a condition called Venous Thromboembolism (VTE), which includes blood clots in veins, by using a combination of medications. Initially, patients will receive Enoxaparin Sodium, an anticoagulant given as a subcutaneous injection, during their hospital stay. This will be followed by taking Eliquis (also known as Apixaban), an oral anticoagulant, twice daily.

The purpose of the study is to evaluate if this treatment approach can effectively prevent VTE in patients with AIHA. The study will last for a total of 24 weeks. During the first 12 weeks, patients will receive the specified medications, starting with Enoxaparin Sodium and then transitioning to Eliquis. The remaining 12 weeks will involve monitoring the patients to see if the treatment successfully prevents the occurrence of VTE.

Participants will be observed for any signs of VTE, such as deep vein thrombosis or pulmonary embolism, and any side effects from the medications. The study will also look at other health factors that might be related to the risk of developing blood clots. This research is important for understanding how to better prevent serious complications in patients with AIHA.

]]> Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab https://clinicaltrials.eu/trial/study-for-patients-with-advanced-malignancies-continued-treatment-with-parsaclisib-alone-or-with-itacitinib-ruxolitinib-ibrutinib-or-tafasitamab/ Wed, 29 Apr 2026 14:24:55 +0000 https://clinicaltrials.eu/trial/study-for-patients-with-advanced-malignancies-continued-treatment-with-parsaclisib-alone-or-with-itacitinib-ruxolitinib-ibrutinib-or-tafasitamab/ This clinical trial is focused on studying treatments for people with advanced cancers and certain immune system diseases. The study involves a medication called parsaclisib, which is being tested either on its own or in combination with other treatments. These additional treatments include itacitinib, ruxolitinib, ibrutinib, and tafasitamab. The purpose of the study is to continue providing treatment and to monitor the safety of these medications in participants who have been part of previous studies involving parsaclisib.

Participants in this study will continue to receive their treatment as they have been, and the study will observe how they respond to the medication over time. The study will not introduce any new treatments but will focus on maintaining the current treatment regimen. The study aims to ensure that participants continue to benefit from the treatment and to gather information on any side effects they may experience.

The study is designed to be open-label, meaning that both the participants and the researchers know which treatments are being administered. This approach helps in closely monitoring the effects of the treatment and ensuring the safety of the participants. The study will continue until the estimated end date, allowing researchers to collect comprehensive data on the long-term effects and safety of the treatments being studied.

]]>